Effect Analysis of Different Doses of Olaparib Combined with Bevacizumab in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer in the Elderly
WANG Shengnan
MA Zhe
MA Xuejiao
Abstract：Objective To analyze the effects of different doses of Olaparib combined with Bevacizumab on clinical ef-ficacy,serum tumor markers and T lymphocyte subsets in elderly patients with platinum-sensitive recurrent ovarian cancer.Methods A total of 140 elderly patients with platinum-sensitive recurrent ovarian cancer diagnosed from January 2019 to Jan-uary 2021 were randomly divided into high-dose group(n=70)and low-dose group(n=70)by envelope method.The low-dose group was treated with Olaparib(150 mg orally,2/d)combined with Bevacizumab injection,and the high-dose group was treated with Olaparib(300 mg orally,2/d)combined with Bevacizumab injection.The median progression-free survival(PFS),disease control rate(DCR),objective response rate(ORR)and the incidence of adverse drug reactions during treat-ment were observed.Serum tumor markers[human epididymal protein 4(HE4),cancer antigen 125(CA125),cancer anti-gen 199(CA199)],T lymphocyte subsets and quality of life scale scores were compared between the two groups before treat-ment and after 2,4 and 6 cycles of treatment.Results After treatment,there was no significant difference in ORR and DCR between the two groups(P＞0.05).Compared with those before treatment,life quality scale scores and peripheral blood CD3+,CD4+,CD4+/CD8+levels in the two groups after 2,4 and 6 cycles of treatment were gradually increased,while serum HE4,CA125 and CA199 levels were gradually decreased(P＜0.05).After 2,4 and 6 cycles of treatment,quality of life scale scores and peripheral blood CD3+,CD4+,CD4+/CD8+levels in low-dose group were higher than those in high-dose group(P＜0.05);however,there was no significant difference in serum HE4,CA125 and CA199 levels between the two groups(P＞0.05).The incidence of adverse drug reactions in low-dose group was lower than that in high-dose group(P＜0.05).After 3 years of follow-up,there was no significant difference in median PFS between the two groups(P＞0.05).Conclusion Low-dose Olaparib combined with Bevacizumab in the treatment of elderly patients with platinum-sensi-tive recurrent ovarian cancer has good clinical efficacy,low incidence of adverse drug reactions and high safety.
Keywords：Ovarian neoplasmsOlaparibBevacizumabHuman epididymis protein 4Cancer antigen 125Quality of lifeT-lymphocyte subsetsAdverse reaction
Publication Date：2025-02-27
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：7( 43-49 )